[go: up one dir, main page]

MA39202B1 - Anticorps humains dirigés contre pd-l1 - Google Patents

Anticorps humains dirigés contre pd-l1

Info

Publication number
MA39202B1
MA39202B1 MA39202A MA39202A MA39202B1 MA 39202 B1 MA39202 B1 MA 39202B1 MA 39202 A MA39202 A MA 39202A MA 39202 A MA39202 A MA 39202A MA 39202 B1 MA39202 B1 MA 39202B1
Authority
MA
Morocco
Prior art keywords
antibodies
antigen
human antibodies
binds
bind
Prior art date
Application number
MA39202A
Other languages
English (en)
French (fr)
Inventor
Andrew Murphy
Gavin Thurston
Nicholas Papadopoulos
Ella Ioffe
Elena Burova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2015/012595 external-priority patent/WO2015112805A1/en
Publication of MA39202B1 publication Critical patent/MA39202B1/fr

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA39202A 2014-01-23 2015-01-23 Anticorps humains dirigés contre pd-l1 MA39202B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461930582P 2014-01-23 2014-01-23
PCT/US2015/012595 WO2015112805A1 (en) 2014-01-23 2015-01-23 Human antibodies to pd-l1

Publications (1)

Publication Number Publication Date
MA39202B1 true MA39202B1 (fr) 2019-04-30

Family

ID=58698441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39202A MA39202B1 (fr) 2014-01-23 2015-01-23 Anticorps humains dirigés contre pd-l1

Country Status (2)

Country Link
AR (1) AR099147A1 (es)
MA (1) MA39202B1 (es)

Also Published As

Publication number Publication date
AR099147A1 (es) 2016-07-06

Similar Documents

Publication Publication Date Title
Chitadze et al. NKG2D-and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors
PH12016501384A1 (en) Human antibodies to pd-l1
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2021009852A (es) Anticuerpos humanos para pd-1.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MX370848B (es) Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MY204733A (en) Anti-pd-l1 antibodies and use thereof
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
SE0402536D0 (sv) Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
MA39202B1 (fr) Anticorps humains dirigés contre pd-l1
MA38501A1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
MA49604A1 (fr) Anticorps humains se liant à pd-1
MA40375A1 (fr) Anticorps humains contre l'hémagglutinine de la grippe
MA37998A1 (fr) Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations
EA202190818A1 (ru) Комбинированная терапия онкологического заболевания
MA42523B1 (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations
HK1228406A1 (en) Human antibodies to pd-1
MA56083B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA50374A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA38502A1 (fr) Anticorps monoclonal humain isole ou son fragment de liaison a l’antigene qui se lie specifiquement a la gremlin-1 humaine utile pour le traitement des fibroses, cancers et l'inhibition de l'angiogenese